Biostar Pharmaceuticals Receivables

Biostar Pharmaceuticals posts a receivables of $460K as of September 2017. That compares with $6.1M in the prior-year period — down 92.4% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Biostar Pharmaceuticals's receivables was $6.1M. The latest reading is $460K — a 92.4% year-over-year decrease (period ending September 2017). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Biostar Pharmaceuticals's financial statement story. At $460K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BSPM's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Biostar Pharmaceuticals's other metric pages and overview cover the third.